Impact of Epoetin β on Quality of Life in Cancer Patients
Author Information
Author(s): Boogaerts M, Coiffier B, Kainz C
Primary Institution: U.Z. Gasthuisberg, Leuven, Belgium
Hypothesis
Does treatment with epoetin β improve the quality of life in patients with cancer-related anaemia compared to standard care?
Conclusion
Epoetin β significantly improves the quality of life and hemoglobin levels in patients with cancer-related anaemia compared to standard care.
Supporting Evidence
- Epoetin β improved quality of life scores significantly compared to standard care.
- 47% of patients receiving epoetin β achieved a significant increase in hemoglobin levels.
- Patients treated with epoetin β reported better overall health and energy levels.
Takeaway
This study shows that a medicine called epoetin β helps cancer patients feel better and have more energy by treating their anemia.
Methodology
This was an open-label, randomised, parallel-group, multicentre, multinational clinical trial conducted over 12 weeks.
Potential Biases
The non-blinded nature of the study may have influenced the results.
Limitations
The study was open-label, which may have influenced patient reporting of quality of life.
Participant Demographics
Patients aged 24-85 years, with a median age of 62, included both males and females with various types of cancer.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI: 1.21–5.13
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website